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Abstract
Introduction: Hematopoietic stem cell transplantation (HSCT) is an aggressive form of therapy which leads to malnutri-
tion requiring nutritional support. The aim of our study was to evaluate if the growth of children is affected by HSCT and 
what the relevant factors are.
Methods: We analyzed changes in anthropometric measures of 79 pediatric patients who underwent allogeneic HSCT. 
Nutritional status was assessed based on weight and height measurements collected prior to HSCT and within 12 months 
post-transplantation. Body weight and height were referred to the age of patients using available z-score calculators.
Results: Compared to the first measurement, the weight-for-age and height-for-age z-scores were significantly reduced 
in all following measurements within a 1-year follow-up. The most severe weight loss occurred on the last day of hospi-
talization related to HSCT, while the height gain declined progressively after HSCT. The presence of acute graft versus 
host disease (GvHD) and the use of a total body irradiation-based regimen were found to be risk factors for a severe 
slowdown of weight gain, while acute GvHD of the gastrointestinal  tract, chronic GvHD and the use of parenteral nutri-
tion were risk factors for a decline in height gain.
Conclusions: Patients treated with allogeneic HSCT demonstrate a reduction in the pace of growth. HSCT recipients 
complicated by GvHD require prolonged and close weight and height monitoring.
Key words: children, hematopoietic stem cell transplantation, nutritional assessment, anthropometric profile
Acta Haematologica Polonica 2021; 52, 2: 110–120
Introduction
Hematopoietic stem cell transplantation (HSCT) is an 
aggressive form of therapy used for malignant and non-
-malignant disorders of the hematopoietic system. Over 
recent years, the annual numbers of both allogeneic and 
autologous HSCTs have been continuously increasing [1]. 
Early- and long-term survival rates have improved, and are 
expected to continue to improve in the coming decades 
due to the enhancement in human leukocyte antigen (HLA) 
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typing, conditioning regimens, supportive and post-trans-
plant care [2]. Today, the probability of 10-year survival is 
85% in 2-year survivors [3].
Nevertheless, there is strong evidence that childhood 
HSCT survivors carry a significantly higher burden of chro-
nic health conditions related to therapeutic exposures than 
do patients treated with conventional therapies and non-
-cancer patients [4]. Taken together, all these factors un-
derscore the need for effective long-term surveillance for 
screening, prevention and maintaining good quality of life.
The nutritional status of HSCT recipients has long been of 
interest to clinicians. Due to ablative therapy, the intensity 
of conditioning regimen and underlying disease, the cata-
bolism of the patient increases and leads to malnutrition, 
which usually requires nutritional support [5]. Other factors 
contributing to impaired weight and height gain are trans-
plant-related complications such as: mucositis, diarrhea, 
nausea, vomiting, and anorexia. These are usually related 
to graft-versus-host disease (GvHD), which interferes with 
the digestion and absorption of nutrients [5].
Several longitudinal studies have reported a significant 
decline in final growth of adult cancer survivors, including 
HSCT recipients [6–8]. The use of total body irradiation and 
certain conditioning regimens have been associated with 
the most severe growth deterioration due to their impact 
on the hypothalamic-pituitary axis and damage to bone 
epiphyses [9–11]. Moreover, the Childhood Cancer Sur-
vivor Study found that patients with certain malignancies 
are more likely to be underweight as adults and to suffer 
from serious medical conditions. This demonstrates the 
need for close surveillance [12].
Since the most dynamic part of the HSCT involves the 
early period after the HSCT [13, 14], patients are at risk of 
malnutrition, and often require nutritional support. Despite 
this fact, there is a paucity of data concerning the impact 
of HSCT on the short-term growth of children, indicating 
a need for further research on an adequate population. 
A significant heterogeneity of patient groups is challen-
ging, since malnutrition and short stature are included in 
the phenotype of some genetic disorders that are treated 
with HSCT. Therefore, studies reporting short-term anthro-
pometric profiles of patients often include different popu-
lations, making proper comparisons problematic [15, 16].
Thus, the purpose of this analysis was to assess the 
changes of anthropometric measures (weight, height) of 
children who underwent HSCT in a one-year follow-up and 
to evaluate any potentially relevant risk factors contribu-
ting to growth disturbances in this population.
Methods
Study design
In this single-institution, retrospective cohort study, we 
enrolled 79 pediatric (under the age of 18) patients who 
received hematopoietic stem cells (HSC) at the Transplan-
tation Center, Children’s University Hospital in Krakow, 
Poland between December 2005 and March 2019. The 
medical records of eligible patients were reviewed and the 
results were drawn up based on a database created by the 
authors. This study was designed and described accor-
ding to the STROBE guidelines for observational studies 
(Table S1 in Supplement 1) [17].
Treatment protocol
The transplant procedure was conducted according to 
institutional procedures and a suitable treatment protocol.
Anthropometric profile
The anthropometric profile of patients was assessed 
based on body weight and height measurements (SECA 
799 Class III Approved Electronic Column Scale with BMI 
function). Calculations based on Center for Diseases 
Control (Medscape, CDC) growth charts were used to 
determine weight-for-age and height-for-age percentiles 
and z-scores in all children. The measurements were 
made during scheduled medical check-ups as part of the 
post-transplant surveillance process. Data concerning 
patients’ body weight and height were collected at four 
time points:
1) up to seven days before HSCT — on admission
2) on the last day of hospitalization related to HSCT — on 
discharge
3) 100 (±14) days post-HSCT
4) 365 (±30) days post-HSCT.
The nutritional status of patients was described based 
on percentile values. Patients were classified as underwei-
ght (<5 percentile), healthy weight (≥5 and <85 percentile), 
overweight (≥85 and <95 percentile), or obese (≥95 per-
centile) according to their weight; and as short stature 
(<5 percentile), normal stature (≥5 and <95 percentile), 
or tall stature (≥95 percentile) according to their height.
Eligibility criteria
Eligible patients were those who underwent allogeneic 
HSCT between December 2005 and March 2019 and 
whose weight and height measurements were collected at 
all the designated time points. To reduce the risk of confou-
nding factors, patients with primary immunodeficiencies or 
other genetic conditions associated with short stature were 
excluded. Other exclusion criteria were: subsequent HSCT, 
death for any reason before the fourth measurement, in-
sufficient information in the medical records, HSCT-related 
hospitalization longer than 86 days, or a period between 
second and third measurements shorter than two weeks. 
None of the patients had received growth hormone (GH) 
therapy within the 12 months prior to HSCT nor in the 12 
months after HSCT. A flowchart outlining the inclusion 
process is presented in Figure 1.
Acta Haematologica Polonica 2021, vol. 52, no. 2
www.journals.viamedica.pl/acta_haematologica_polonica112
Measured outcomes
The primary endpoints of our study included an evaluation 
of patients’ anthropometric profiles within one year after 
transplantation, i.e. changes of weight-for-age and height-
-for-age z-scores in four time points.
The secondary endpoints comprised analysis of po-
tentially relevant factors contributing to growth slowdown. 
We analyzed differences between first and fourth measu-
rements in weight-for-age and height-for-age z-scores in 
subgroups derived from selected baseline characteristics 
of patients and transplant complications. These included: 
age (<10 and ≥10 years), sex, type of disease, type of pre-
-transplant conditioning, the use of total body irradiation 
(TBI)-based regimen and parenteral nutrition, the presence 
of stage III–IV mucositis, acute GvHD (graded according to 
Keystone Consensus [18]), acute GvHD of the gastrointe-
stinal (GI) tract, chronic GvHD (diagnosed within 365 days 
after transplantation), and chronic GvHD of the GI tract.
Statistical analysis
Prior to statistical analysis, all patients with missing 
data or who were lost to follow-up were excluded. Con-
tinuous variables are presented as mean ±standard 
deviation (SD) or median and interquartile range [IQR], 
as appropriate. Categorical variables are expressed as 
numbers and percentages. For normality assessment, 
the Shapiro–Wilk test was used. Continuous variables 
were compared between two related and non-related 
groups using the Wilcoxon signed-rank test and Mann-
-Whitney U test, respectively. P-values of less than 0.05 
were considered statistically significant. Data analysis 
was done with STATISTICA 13.0 software (StatSoft Inc., 
Tulsa, OK, USA).
Ethical statement
All procedures performed in this study involving human par-
ticipants were in accordance with the ethical standards of 
the institutional and national research committee and with 
the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. Informed consent was not 
required in this type of study. This study was approved by 
the Ethics Committee of Jagiellonian University.
Results
Patient characteristics
A total of 79 pediatric patients (54 male, 25 female) 
underwent allogeneic HSCT as a treatment for malignant 
disease (61; 77.22%) or acquired non-malignant disease 
(18; 22.78%). The mean ±SD age on admission was 116.32 
±58.79 months. Fifty-eight (73.42%) patients received pre-
-transplant myeloablative therapy, and in 31 (39.24%) of 
them a TBI-based regimen was used. Forty-seven (59.49%) 
patients received HSC from an unrelated donor and 32 
(40.51%) from a related donor, comprising 28 from an 
HLA-matched sibling donor (35.44%), and four from an 
HLA-family donor (5.06%). Donors were men in 43 (54.43%) 
cases and women in 36 (45.57%) cases, with a mean age 
of 23.53 ±10.23 years. Bone marrow was a graft source 
in 74 (93.67%) patients, peripheral stem cells were used 
in four (5.06%) patients, and cord blood in one (1.27%) 
patient. Hematopoietic reconstitution was completed in all 
patients. The median (IQR) length of hospitalization related 
to HSCT was 36 (32–44) days. The time between first and 
third measurements was 97 (91–104) days, and between 
first and fourth measurements was 362 (356–373) days. 
Transplant-related complications included mucositis in 
69 (87.34%) patients, acute GvHD in 26 (34.57%), chro-
nic GvHD in 25 (31.65%), fever of unknown origin in 59 
(74.68%), veno-occlusive disease in three (3.80%), and 
engraftment syndrome in 11 (13.92%). Patient and trans-
plant characteristics are set out in Table I.
Primary endpoints
The anthropometric profiles of all eligible (n =79) patients 
were expressed as mean values with standard deviations 
of weight-for-age and height-for-age z-scores (Figures 2A 
and 2B).
Weight
At baseline, four (5.06%) patients were classified as under-
weight, 52 (65.82%) as healthy weight, 16 (20.25%) as 
overweight, and seven (8.86%) as obese. The mean values 
of weight were 36.37 kg, 33.89 kg, 34.71 kg and 37.66 kg 
at the first, second, third and fourth measurements, 
respectively. The weight-for-age z-scores in subsequent 
measurements were: 0.11, –0.39, –0.35 and –0.21, 
respectively. Compared to the first measurement (on 
admission), the weight-for-age z-scores were significantly 
reduced in all following measurements within the 1-year 
follow-up (Table II). The lowest value of weight-for-age 
z-scores was noted at the second measurement (on 
discharge).
Figure 1. Flowchart of patient inclusion
Consecutive patients who
underwent HSCT
between 2005 and 2019
(n =181)
Patients who underwent 
HSCT as a treatment 
of congenital non-malignant 
disease (n =47)
Patients who underwent 
HSCT as a treatment 




• death within I year 
posttransplant (n =18)
• lack of measurement 
at designated time or loss 
of follow-up (n =33)
• hospitalization related 
to HSCT longer than 
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Height
In the first measurement, four (5.06%) patients were clas-
sified as short stature, 71 (89.87%) as normal stature, and 
four (5.06%) as tall stature. Patients’ mean height expres-
sed in meters was 1.34, 1.34, 1.35 and 1.38 in the first, 
second, third and fourth measurements, respectively. The 
Table I. Demographics of patients and hematopoietic stem cell transplantation (HSCT) characteristics
Parameter n Number of patients
Peripheral blood stem cells 79 4 (5.06%)
Cord blood 79 1 (1.27%)
HLA-matching, n [%] 79 62 (78.48%)
Myeloablative conditioning,  
n [%]
79 58 (73.42%)




Parenteral nutrition in HSCT 
period, n [%]
79 50 (63.29%)
Time between HSCT and second 
measurement (days), median 
[IQR]
79 36.00  
[32.00–44.00]
Time between HSCT and third 
measurement (days), median 
[IQR]
79 97.00  
[91.00–104.00]
Time between HSCT and fourth 
measurement (days), median 
[IQR]
79 362.00  
[356.00–373.00]
Transplant complications,  
n [%]
Mucositis: 79 69 (87.34%)
• stage I–II 35 (44.30%)
• stage III–IV 34 (43.04%)
Acute GvHD: 79 26 (34.57%)
• stage I–II 19 (24.05%)
• stage III–IV 7 (8.86%)
• gastrointestinal tract 13 (17.28%)
• liver 3 (4.94%)
• skin 25 (33.33%)
Fever of unknown origin 79 59 (74.68%)
Veno-occlusive disease 79 3 (3.80%)
Engraftment syndrome 79 11 (13.92%)
Chronic GvHD: 79 25 (31.65%)
• gastrointestinal tract 12 (15.19%)
• skin 19 (24.05%)
• liver 11 (13.92%)
• lungs 9 (11.39%)
SD — standard deviation; CR — complete remission; MSD — matched-sibling donor; MUD — matched-unrelated donor; MFD — matched-family donor; HLA — human leukocyte antigen; TBI — total body irradia-
tion; IQR — interquartile range; GvHD — graft-versus-host disease
Parameter n Number of patients
Sex, n (% of males) 79 54 (68.35%)
Age on admission (months), 
mean ±SD
79 116.32 ±58.79
Age group, n (%)
<10 years 79 40 (50.63%)
≥10 years 79 39 (49.37%)
Transplant indication, n (%)
Malignant 79 61 (77.22%)
Non-malignant 79 18 (22.78%)
Disease, n (%)
Acute lymphoblastic leukemia 
(ALL)
79 32 (40.51%)
Severe aplastic anemia (SAA) 79 19 (24.05%)




Juvenile chronic myeloid leuke-
mia (JMML)
79 3 (3.80%)
Autoimmune disease 79 2 (2.53%)




Non-Hodgkin’s lymphoma (NHL) 79 2 (2.53%)
Disease stage  
before HSCT, n [%]
No remission 79 34 (43.04%)
CR I 79 21 (26.58%)
CR II 79 23 (29.11%)
CR >II 79 1 (1.27%)
Donor type, n [%]
MSD 79 28 (35.44%)
MUD 79 47 (59.49%)
MFD 79 4 (5.06%)
Donor age (years), mean ±SD 79 23.53 ±10.23
Donor sex, n (% of males) 79 43 (54.43%)
Source of stem cells, n [%]
Blood marrow 79 74 (93.67%)
mean height-for-age z-scores were: –0.03, –0.15, –0.15, 
–0.34. Similarly to weight, the height-for-age z-scores in the 
second, third and fourth measurements were significantly 
diminished compared to the first measurement (Table II). 
But in contrast to the weight profile, the greatest drop in 
height-for-age values occurred at one year post-transplant.
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Figure 2. Charts presenting mean ±standard deviation (SD) values of z-scores of A — weight, B — height, measured at designated time points
Table II. Patient weight in kilograms and height in meters with z-scores at four time points. All values expressed as mean ±standard de-
viation (SD
















































































































Figure 3. Differences between fourth [365 days after hematopoiet-
ic stem cell transplantation (HSCT)] and first (on admission) mea-
surements expressed in z-scores. Each point refers to one patient
The differences in the weight-for-age and height-for-age 
z-scores between the fourth and the first measurements 
are shown in Figure 3.
Secondary endpoints
At one year post-transplant, declines in weight-for-age 
and height-for-age z-scores had occurred in all analyzed 
subgroups. Acute GvHD and the use of a TBI-based con-
ditioning regimen were the significant factors influencing 
weight (mean ±SD difference in weight-for-age z-scores 
values: –0.53 ±1.19 vs. –0.22 ±0.83, for patients with 
and without acute GvHD, respectively, and –0.59 ±0.88 
vs. –0.14 ±0.98, for patients who received and did not 
receive TBI, respectively). Other analyzed factors, which 
were sex, age (<10 years vs. ≥10 years), type of disease 
(malignant vs non-malignant), parental nutrition in HSCT 
period, the presence of III–IV mucositis, acute GvHD of 
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the GI tract, were not significantly associated with the 
weight difference.
Our analysis of differences in height-for-age z-scores re-
vealed that patients with GI manifestation of acute GVHD 
and with chronic GVHD presented significantly greater 
decreases in height gain than did patients without these 
complications (mean ±SD difference in height-for-age 
z-scores values: –0.51 ±1.31 vs. –0.23 ±0.53 for patients 
with and without acute GvHD of GI tract, respectively, and 
–0.41 ±1.08 vs. –0.22 ±0.45 for patients with and with-
out chronic GvHD, respectively). Moreover, patients who re-
ceived parenteral nutrition during the peritransplant period 
presented a greater decline in height gain than did those 
without parenteral nutrition (mean ±SD difference in height- 
-for-age z-scores values: –0.39 ±0.83 vs. –0.08 ±0.39 for 
patient with and without parenteral nutrition, respective-
ly; p =0.006). Sex, age (<10 years vs. ≥10 years), type of 
disease (malignant vs non-malignant), the use of TBI, the 
presence of III–IV mucositis, acute GvHD and GI manifes-
tation of chronic GvHD were not significantly associated 
with height differences. The results of the comparisons 
are set out in Table III.
Discussion
Our study aimed to assess the influence of HSCT on the 
growth and body mass of children with malignant or acqui-
red non-malignant diseases in a one-year follow-up. We 
found that patients treated with allogeneic HSCT demon-
strated a severe reduction in the pace of growth, and were 
unable to achieve their baseline z-score values one-year 
post-transplant.
Moreover, we demonstrated that the presence of acute 
and chronic GvHD, GI manifestation of acute GvHD, as well 
as the use of TBI-based regimens and parenteral nutrition, 
are potential risk factors for a severe slowdown of growth.
HSCT is a commonly used therapeutic procedure for ma-
lignant and non-malignant disorders of the hematopoietic 
system. In most cases, it comprises myeloablative radio- or 
chemotherapy, infusion of hematopoietic stem cells, and 
complex immunosuppression [19]. The most dynamic 
part of the procedure involves the early period after HSCT 
[13, 14]. As a result of ablative therapy, the intensity of 
the conditioning regimen, and the underlying disease, the 
catabolism of the patient increases and can lead to malnu-
trition, often requiring nutritional support [5]. Other factors 
contributing to possible weight loss are transplant-related 
complications such as: mucositis, diarrhea, nausea, vomi-
ting, and anorexia. These are usually related to GvHD, which 
interferes with the digestion and absorption of nutrients [5]. 
Since nutritional status is an essential factor in determining 
the proper development and health status of children, it 
is of interest to many clinicians. Several studies have as-
sessed the impact of nutritional status prior to HSCT on its 
outcomes, but their results remain ambiguous, particularly 
in pediatric populations.
The aim of our study was to analyze the anthropometric 
profile of patients before and up to one year after HSCT. We 
found a significant weight loss and a slowdown in height 
gain in the early period after transplantation. The height 
gain continued to slow down until one year post-transplant, 
but a catch-up in weight occurred. Despite that, children 
did not reach their baseline z-score values one-year post-
-transplant. To date, only a few studies have reported the 
short-term follow-up nutritional profiles of pediatric HSCT 
recipients with various underlying conditions. Some of 
them have aimed to determine the efficacy and outcomes 
of enteral and/or parenteral nutrition and reported short-
-term evaluations of nutritional status [20–23]. Patients 
receiving enteral nutrition had lower weight-for-height z-
-scores than those receiving parenteral nutrition on ad-
mission and 30 days post-transplant [20]. Analysis of the 
anthropometric profile of patients with Fanconi anemia sho-
wed a significant decline in nutritional status (weight loss 
and decrease in height-for-age and BMI-for-age z-scores) 
at 30 days after HSCT [16]. Campos et al. [24] found no 
significant reduction in z-scores for weight-for-age, height-
-for-age, or body mass index (BMI)-for-age in 25 children 
at 12-months post-transplant. A recent study on 27 chil-
dren with primary immunodeficiencies showed a progressi-
ve catch up for weight (–0.27) but no catch up for height 
(–0.93) in a one-year follow up after a primary decrease 
in anthropometric measures soon after HSC [15]. This is 
wholly consistent with our findings. Nonetheless, before 
transplantation mean weight and height z-scores of tho-
se patients were below average, and one-third of children 
had a weight and/or height ≤–2 SD, in contrast to our po-
pulation which was above average (0.11 z-score for height 
and –0.03 z-score for weight), with only 5% of our patients 
being below the 5th percentile of weight and height. Given 
that we excluded patients with genetic non-malignant con-
ditions, our study group would seem to reflect a healthy 
population and to be a good model to show alterations in 
growth patterns.
HSCT is a factor demonstrated as altering final height 
of children in a longitudinal follow-up [6–8]. Growth defi-
cits have been associated with cranial radiotherapy, spinal 
irradiation of ≥7 vertebrae, administration of certain con-
ditioning regimens (lomustine, busulfan), pre-transplant 
body height, and young age [9, 25]. Among these factors, 
conditioning regimens (total body irradiation, busulfan, cyc-
lophosphamide, melphalan) have been found to be one of 
the most important factors affecting final height of cancer 
survivors, as they exert an effect on the hypothalamic-pi-
tuitary axis, endocrine glands function, and cause dama-
ge to bone epiphyses [9–11]. Since GH deficiency is one 
of the most common endocrinopathies among childhood 
cancer survivors, GH therapy offers possible beneficial 
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Table III. Evaluation of anthropometric profile of patients according to weight-for-age and height-for-age z-scores differences between fou-
rth (365 days post-transplant) and first (on admission) measurements
Parameter n Difference in weight-for-age z-score values* p-value
Difference in height-for-age 
z-score values* p-value
All patients 79 –0.32 ±0.96 –0.28 ±0.72
Age group 0.17 0.12
<10 years 39 –0.44 ±1.07 –0.38 ±0.91
≥10 years 40 –0.20 ±0.83 –0.18 ±0.46
Sex 0.16 0.26
Male 54 –0.24 ±1.01 –0.23 ±0.79
Female 25 –0.49 ±0.83 –0.38 ±0.55
Type of disease 0.16 0.95
Malignant 61 –0.38 ±1.03 –0.26 ±0.77
Non-malignant 18 –0.09 ±0.66 –0.34 ±0.51
Type of pretransplant conditioning 0.09 0.11
Myeloablative 58 –0.44 ±0.9 –0.37 ±0.58
Non-myeloablative 21 0.03 ±1.05 –0.02 ±0.98
TBI-based regimen 0.01 0.48
Yes 31 –0.59 ±0.88 –0.33 ±0.53
No 48 –0.14 ±0.98 –0.24 ±0.82
Parenteral nutrition in HSCT period 0.56 0.01
Yes 50 –0.33 ±1.14 –0.39 ±0.83
No 29 –0.30 ±0.54 –0.08 ±0.39
Stage III–IV mucositis 0.71 0.49
Yes 34 –0.30 ±0.88 –0.22 ±0.53
No 45 –0.33 ±1.03 –0.33 ±0.85
Acute GvHD 0.047 0.75
Yes 26 –0.53 ±1.19 –0.27 ±1.00
No 53 –0.22 ±0.83 –0.30 ±0.54
Acute GvHD of gastrointestinal tract 0.17 0.01
Yes 13 –0.38 ±1.50 –0.51 ±1.31
No 66 –0.31 ±0.54 –0.23 ±0.53
Chronic GvHD 0.2 0.04
Yes 25 –0.42 ±1.31 –0.41 ±1.08
No 54 –0.27 ±0.76 –0.22 ±0.45
Chronic GvHD of gastrointestinal tract 0.11 0.05
Yes 12 –0.79 ±0.88 –0.69 ±0.72
No 67 –0.23 ±0.96 –0.2 ±0.7
*Fourth vs. first measurement; TBI — total body irradiation; HSCT — hematopoietic stem cell transplantation; GvHD — graft versus host disease
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management of decreased growth [10]. Additionally, only 
a few studies have aimed to investigate nutritional status 
and body composition abnormalities in cancer survivors. 
A report of the Childhood Cancer Survivor Study showed 
that underweight HSCT survivors are more likely to suffer 
from major medical conditions, and need to be monitored 
for negative health consequences of abnormal BMI [12].
Our study is one of the first to investigate the risk factors 
for early growth retardation in children treated with HSCT. 
So far, few studies have focused on this issue. A short-term 
follow-up study comprising 123 adult patients found that 
being male, an allogeneic transplant, and a length of stay in 
hospital >21 days were all factors associated with greater 
deterioration of nutritional status [26]. Moreover, Campos 
et al. found that total dose of corticosteroids, length of their 
use, and the type of HSCT donor were all risk factors for 
lean body mass changes in a 6-month follow-up period [24].
We found the presence of acute GvHD to be a possible 
factor impeding weight gain, and we found acute GvHD of 
the GI tract or chronic GvHD to affect height gain. Acute 
and chronic GvHD include multiple manifestations and 
can affect any segment of the GI tract, causing a variety 
of GI symptoms. Mucosal injury of intestines results in 
protein loss, which subsequently leads to malabsorption 
and malnutrition [27]. To date, the results describing the 
association between acute GvHD and weight and height 
changes are inconsistent. Contrary to our study, a report 
on 45 children treated with HSCT showed no association 
between the presence of GI symptoms in patients with 
GvHD and anthropometric measurements four months 
after HSCT; however, this study group was relatively small, 
which might have impeded analysis [28]. Chronic GvHD is 
a leading cause of long-term mortality in HSCT recipients 
and can occur at any time after HSCT. To date, a few studies 
have shown that patients with chronic GVHD were more 
likely to report shorter final height and significant weight 
loss [10, 29].
TBI remains a well-known factor altering final height of HSCT 
recipients due to its impact on endocrine and skeletal sy-
stems [8, 11]. Our study found it to be also an important risk 
factor for weight loss in short-term follow-up. Furthermore, 
we demonstrated that the use of parenteral nutrition in the 
peritransplant period is a risk factor for a severe deterio-
ration in height gain. According to the ESPEN Guidelines, 
parenteral nutrition is recommended as nutritional support 
where oral and enteral nutrition is insufficient or unfeasible 
[30]. As far as we know, there has been no study evaluating 
the height of patients who underwent HSCT and who were 
fed with parenteral nutrition. A recent systematic review 
found that patients receiving enteral nutrition had lower 
weight-for-height z-scores than those receiving parenteral 
nutrition on admission and 30 days post-transplant. Howe-
ver, it did not evaluate the height of patients [20].
Our study has several limitations. Firstly, due to the 
low number of pediatric HSCT recipients, our study group 
(79 patients) is relatively small. Secondly, our study inclu-
ded only Polish children; the anthropometric profile may 
differ in other populations. Our results cannot be easily 
extrapolated to patients with primary immunodeficiencies 
and short stature phenotype, since they were excluded 
from the study.
Nevertheless, thanks to this criterion, our study group se-
ems to present a healthy population and to be a good model 
to show alterations in growth patterns. Another downside 
is the retrospective character of this study and the limita-
tions linked to that. Due to this fact, we were confronted by 
missing data, and as a result had to exclude some patients.
Conclusions
In conclusion, we demonstrated that weight-for-age and 
height-for-age z-scores of pediatric patients significantly 
declined throughout a one-year follow-up. Patients who 
received TBI before HSCT, who were fed with parenteral 
nutrition, or who were complicated with GvHD, especially 
localized in the GI tract, require prolonged and close weight 
and height monitoring, since we have found them to be 
at increased risk for deteriorations in weight and height 
gain. Future larger studies are warranted to validate these 
findings.
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